| Name | Title | Contact Details |
|---|
LRS Healthcare is a medical staffing agency that connects nursing and allied healthcare professionals to facilities nationwide.
Herself Health is a primary care practice designed for women 65 and up, offering female-focused, age-conscious services that consider every part of health: physical, emotional, spiritual, sexual, and social. Herself Health provides person-centered, value-based care to women 65+ with a focus on mind, body, and soul. This holistic approach to care delivery aims to improve the quality of life of both the women for whom we care and the clinical team of physicians, nurses, and medical assistants. We realize that health is more than just healthcare and our goal is to help each Herself woman live her best life.
F-D-C Reports, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Coriell Institute for Medical Research is a Camden, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.